abs199.txt	purpose		prognostic	value	of	pathologic	complete	response	(pcr)	and	extent	ofpathologic	attained	with	anthracycline-free	platinum	plus	taxaneneoadjuvant	chemotherapy	(nac)	in	triple-negative	breast	cancer	(tnbc)	isunknown	we	report	recurrence-free	survival	(rfs)	overall	(os)according	to	degree	patients	treated	carboplatinplus	docetaxel	nac	experimental	design	one-hundred	ninety	withstage	i-iii	tnbc	were	neoadjuvant	carboplatin	(auc6)	docetaxel(75	mg/m2)	every	21	days	×	6	cycles	pcr	(no	evidence	invasive	tumor	breastand	axilla)	residual	burden	(rcb)	evaluated	werefollowed	for	recurrence	wasassociated	rfs	os	using	the	kaplan-meier	method	results	median	age	was51	years	52%	node-positive	rcb	i	rates	55%	13%	respectively	five	percent	0%	58%	rcbii/iii	received	adjuvant	anthracyclines	three-year	79%and	87%	was	90%	66%	inthose	without	[hr	=	0	30	95%	confidence	interval	(ci)	14-0	62	p	=0	0001]	94%	79%	those	pcr(hr	25	ci	10-0	63	001)	demonstrated3-year	(93%)	(100%)	similar	on	multivariableanalysis	higher	stage	node	positivity	ii/iii	associatedwith	worse	conclusions	yieldsencouraging	efficacy	achieving	or	this	regimendemonstrate	excellent	3-year	anthracycline	clincancer	res	1-10	©2018	aacr
